Olympia Pharmacy Recalls Adenosine Injection Due to Sterility Concerns
Olympia Pharmacy is recalling Adenosine-Mono-Phosphate Injection because FDA inspections raised concerns about quality control and sterility assurance.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II and involves a lack of assurance of sterility in an injectable drug, which poses a significant risk of infection or serious injury.
Plain-English summary
Lowlite Investments, Inc. D/B/A Olympia Pharmacy is recalling Adenosine-Mono-Phosphate Injection, 200 mg/ml. The product was compounded by Olympia Pharmacy in Orlando, FL, and distributed nationwide and to Puerto Rico. The specific lot code is A5631 with an expiration date of 12/31/13.
The recall was initiated because FDA inspection findings resulted in concerns regarding quality control processes, specifically a lack of assurance of sterility. The agency has classified this recall as Class II.
Consumers and healthcare providers should stop using the recalled product and contact their pharmacist or the recalling firm for instructions on how to return or dispose of the medication.
The recalled product
- Product
- Adenosine-Mono-Phosphate Injection, 200 mg/ml, compounded by Olympia Pharmacy, Orlando, FL
- Manufacturer
- Lowlite Investments, Inc. D/B/A Olympia Pharmacy
- Category
- Drug — Injectable
- Affected units
- 1
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- A5631 exp 12/31/13
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 105 recalled by Lowlite Investments, Inc. D/B/A Olympia Pharmacy under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 105 products in this recall →Related recalls
Same manufacturer · Lowlite Investments, Inc. D/B/A Olympia Pharmacy
See all →- SevereOlympia Pharmacy Recalls Diclazuril Injection Due to Sterility Concerns
FDA (Drugs) · 2013-07-17
- HighOlympia Pharmacy Recalls Metabolase Injection Due to Sterility Concerns
FDA (Drugs) · 2013-07-17
- SevereOlympia Pharmacy Recalls Oxytocin Injection Due to Sterility Concerns
FDA (Drugs) · 2013-07-17
- SevereOlympia Pharmacy Recalls Betamethasone Injection Due to Sterility Concerns
FDA (Drugs) · 2013-07-17
- SevereOlympia Pharmacy Recalls HACC 270.1 Injection Due to Sterility Concerns
FDA (Drugs) · 2013-07-17
Same hazard · sterility
See all →- SevereK.C. Pharmaceuticals Recalls Target Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tri-MIX Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Semaglutide/Cyanocobalamin Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereFDA Recalls Tirzepatide Injectable Due to Sterility Concerns
FDA (Drugs) · 2026-10-14
- SevereK.C. Pharmaceuticals Recalls Leader Advanced Relief Eye Drops for Sterility Concerns
FDA (Drugs) · 2026-10-14
Similar recalls
- SeverePharmakon Recalls Adenosine Injection Due to Sterility Concerns
FDA (Drugs) · 2016-07-20
- HighFDA Recalls Amino Blend Injectable Vials Due to Sterility Concerns
FDA (Drugs) · 2022-06-01
- SeverePharmedium Recalls Adenosine Injection Due to Sterility Assurance Concerns
FDA (Drugs) · 2018-02-28
- HighFDA Recalls Olympia Mineral Blend Injectable for Lack of Sterility Assurance
FDA (Drugs) · 2022-06-01
- HighFormula F2 Compounded Injectable Medication Recalled for Sterility Assurance Failure
FDA (Drugs) · 2022-06-01
- HighCompounded Injectable Medication Recalled Due to Sterility Assurance Failure
FDA (Drugs) · 2022-06-01